OZEM vs THNR: Holdings Overlap & Returns
Over the year to Nov 13, 2026, OZEM returned +0.7% to THNR's +6.7%; 64% of their weight is in the same names.
- Return gap
- +6.0 pts1 year to Nov 13, 2026: THNR ahead, total return
- Fee gap
- 0.00 ptsA year: both 0.59%, per filings dated Jan 28, 2026 and Apr 30, 2026
- Overlap
- 64%Share of the two books held in common, holdings dated Nov 13, 2026
- Net flow
- −$1m / −$791kOZEM / THNR, Oct 13, 2026 to Nov 12, 2026, daily basis
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
OZEM +0.7%, THNR +6.7%: THNR +6.0 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in THNR costs about $14.00 one way and $28.00 in and out, at a median spread of 0.28%. The 0.28% spread is THNR’s 30-day median, from Amplify (fund page).
Fees over time
Hypothetical. $10,000 in OZEM for 10 years at 0.59% a year costs about $972 in fees and lost growth; THNR at 0.59% would cost $972. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
30% of OZEM's weight is in S&P 500 companies and 70% is outside the index. Holdings as of Nov 13, 2026.
46% of THNR's weight is in S&P 500 companies and 54% is outside the index. Holdings as of Nov 13, 2026.
Key numbers
Both cost 0.59% a year; their one-year returns differ by 6.0 points; OZEM is 11.0 times larger.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +0.7% | +6.7% |
|---|---|---|
| Below its all-time high | 15.1%, high on Jan 26, 2026 | 6.3%, high on Aug 25, 2026 |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.59% | 0.59% |
| Net assets, as of Nov 12, 2026 | $57m | $5.2m |
| Active share vs the S&P 500 | 98% | 96% |
| Holdings in common | 64% |
The numbers behind it
Net assets: $57m on Nov 13, 2026 for Roundhill GLP-1 & Weight Loss ETF, and $5.2m on Nov 12, 2026 for Amplify Weight Loss Drug & Treatment ETF.
Holdings in common uses holdings dated Nov 13, 2026.
What they share
By the books each fund has filed, OZEM and THNR hold 64% of their money in the same securities at the same weight. Holdings dated Nov 13, 2026.
half
64% in common
Held in common
Show all 12 holdings
| Eli Lilly & Co | 20.30% | 12.10% |
| Novo Nordisk A/S | 10.86% | 8.89% |
| Pfizer Inc | 5.69% | 5.24% |
| Chugai Pharmaceutical Co Ltd | 6.82% | 5.17% |
| CSPC Pharmaceutical Group Ltd | 4.56% | 4.44% |
| Viking Therapeutics Inc | 3.94% | 4.43% |
| AstraZeneca PLC | 3.22% | 5.79% |
| Hanmi Pharm Co Ltd | 6.97% | 3.19% |
| Zealand Pharma A/S | 3.12% | 3.29% |
| Amgen Inc | 2.99% | 6.11% |
| Roche Holding AG | 2.70% | 5.68% |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 4.16% | 2.27% |
Only in OZEM
Show all 5 holdings
| Hansoh Pharmaceutical Group Co Ltd | 3.77% |
| Ascletis Pharma Inc | 3.36% |
| Gubra A/S | 2.14% |
| United Laboratories International Holdings Ltd | 2.03% |
| MBX Biosciences Inc | 1.75% |
Only in THNR
Show all 5 holdings
| Regeneron Pharmaceuticals Inc | 6.05% |
| AbbVie Inc | 5.65% |
| Merck & Co Inc | 4.98% |
| Arrowhead Pharmaceuticals Inc | 2.81% |
| Invesco Government & Agency Portfolio 12/31/2031 | 0.47% |
Side by side
Open the table
| Fund | Roundhill GLP-1 & Weight Loss ETF · Holds 21 stocks in healthcare innovation and GLP-1, 30% of its weight in S&P 500 companies | Amplify Weight Loss Drug & Treatment ETF · Holds 21 stocks in healthcare innovation and GLP-1, 46% of its weight in S&P 500 companies |
| Issuer | Roundhill | Amplify |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 30.4% | 45.8% |
| Active share vs the S&P 500 | 97.8% | 96.5% |
| In the Nasdaq-100 | 4.4% | 17.8% |
| Holdings | 21 | 21 |
| Top ten, share of the fund | 72.0% | 66.3% |
| Expense ratio | 0.59% | 0.59% |
| Fee for the differing part | 0.60% | 0.61% |
| Total return, 1 year | +0.7% | +6.7% |
| vs its benchmark | not measured | not measured |
| Below its high | −15.1% | −6.3% |
| Net assets, OZEM as of Nov 13, 2026 and THNR as of Nov 12, 2026 | $57m | $5.2m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | −4.9% | −0.1% |
|---|---|---|
| 6 months | +1.8% | +7.0% |
| 1 year | +0.7% | +6.7% |
| Since launch (OZEM May 2024 · THNR May 2024) | +25.6% | +5.6% |
About OZEM
By weight, 30% of OZEM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 72% of the fund across 21 positions, as published by its issuer for Nov 13, 2026.
More
Over the year to Nov 13, 2026 the fund returned +0.7% with distributions reinvested. It sits 15.1% below its all-time high of Jan 26, 2026.
About THNR
By weight, 46% of THNR's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 66% of the fund across 21 positions, as published by its issuer for Nov 13, 2026.
More
Over the year to Nov 13, 2026 the fund returned +6.7% with distributions reinvested. It sits 6.3% below its all-time high of Aug 25, 2026.
64% of the two portfolios are the same securities at the same weight.
Questions people ask
Do OZEM and THNR hold the same stocks?
By their latest filings, 64% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, OZEM against THNR, data as of Nov 13, 2026. https://etfiq.com/compare/themes/ozem-vs-thnr
ETFIQ. (Nov 13, 2026). OZEM against THNR. Retrieved from https://etfiq.com/compare/themes/ozem-vs-thnr
[OZEM against THNR (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/ozem-vs-thnr)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.